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There is general agreement that the manner medicine is currently practiced is not adequate for
addressing all health relevant issues in a way that would be most beneficial for all patients and that
we need a new modern medicine. Even candidates for such a modern medicine have been recently
nominated in the form of (I) personalizedmedicine, (II) precisionmedicine, (III) P4medicine, (IV)
P5 medicine, and (V) stratified medicine, which we will review briefly. The purpose of our opinion
paper is to emphasize the urgent need for a formal definition in terms of the experimental design of
modern medicine in order to deal efficiently with the opportunities provided by high-throughput
genomic data and that all the current candidate programs mentioned above are lacking such a
formalization.
In order to reveal these shortcomings and to see the need for revised formulations, we provide
in the following a brief account on the proposed approaches (I–V). According to the Committee
on a Framework for Development a New Taxonomy of Disease, National Research Council (2011):
‘Precision medicine’ refers to the tailoring of medical treatment to the individual characteristics of each
patient. It does not literally mean the creation of drugs or medical devices that are unique to a patient,
but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a
particular disease, in the biology and/or prognosis of those diseases they may develop, or in their response
to a specific treatment. Preventive or therapeutic interventions can then be concentrated on those who
will benefit, sparing expense and side effects for those who will not.
For personalized medicine the committee gives the exact same definition, with the difference of
omitting the italic parts in the above statement. Furthermore, it mentions that:
Although the term ‘Personalized Medicine’ is also used to convey this meaning, that term is sometimes
misinterpreted as implying that unique treatments can be designed for each individual.
P4 medicine (Personalized, Predictive, Preventive, Participatory) (Weston and Hood, 2004) has
been proposed by Leroy Hood. Its basic idea is founded on systems biology and the fact that
the function of genes and gene products unfolds via different types of interaction networks, e.g.,
the protein interaction network or the transcriptional regulatory network of cells and the intra
network interactions among these networks (Kauffman, 1969). Hood emphasizes the need for
a cross-disciplinary environment because only this enables an effective integration of biology,
technology and computation/mathematics in order to establish P4 medicine. Unfortunately, no
quantitative approach is defined. Interestingly, further qualitative extensions to P4 medicine have
been suggested by Gorini and Pravettoni (2011) named P5 medicine, where the additional “P”
represents psycho-cognitive aspects and Khoury et al. (2012) arguing that the population perspective
Emmert-Streib et al. Defining Modern Medicine
to the system needs to receive more emphasize. Finally, stratified
medicine aims, compared to the above programs, to more
modest goals, trying to connect patient’s subpopulations via
clinical biomarkers to therapeutic responses (Trusheim et al.,
2007). Although, also this program describes only a qualitative
approach, it is clear that the practical carrier of this approach
are clinical biomarkers opening the door for all types of high-
throughput Omics and imaging technologies. However, this
assumes biomarkers are well defined. Here it is important to
emphasize that the National Biomarker Development Alliance
reveiced recently the definition of “a biomarker” because it
has been realized that previous definitions contain systematic
shortcomings.
From the brief outline of the five modern medicine programs
above, we think it is fair to assert that each of them is qualitative
in nature, in the sense that it would not entail a quantitative
definition in statistical terms of the required experimental
design (Hinkelmann and Kempthorne, 2008). However, this
is a tremendous shortcoming because each of these modern
medicine programs will be based on genomics data, which
can only be utilized beneficially if one specifies the way they
should be used with sufficient detail. Particularly, this requires
the full specification of every step from the generation of the
data down to their analysis, in order to ensure the optimal
value for the patients and all statistical necessities, including the
robustness and the reproducibility of the obtained results (Peng,
2011).
For instance, although the above five novel approaches to
medicine are based on Omics data, none is explicit enough
to identify the population under investigation for a particular
problem category. As an example, randomized clinical trials, the
gold standard of the “old medicine” use statistical hypothesis
testing to decide about the effect of a new treatment or drug
w.r.t. clinical outcome endpoints, whereas patients correspond
to samples in a trial. Will the new approaches to medicine
involve statistical hypothesis testing too, we think so, but what
is then a sample? If it is a patient then what is the difference
to our current approach? If one uses clinical biomarkers to
stratify patients into smaller subpopulations (subgroups) of
patients, will there be enough patients in these strata to allow
for enough power of a statistical test? For orphan diseases this
is certainly questionable because the number of cases is limited.
As an extreme example consider Ribose-5-phosphate isomerase
deficiency with a single diagnosed patient. Would any of the
five new medicine programs provide a solution for this, or are
such disorders excluded? If they are excluded, were to draw
the line for exclusion? Would this imply that for the left out
disorders we need yet another new medicine 3.0? These are just
a few arguments that come to mind for which we cannot find
satisfactory answers in the proposed agendas. Overall, we think
that further qualitative refinements of such programs are not
fruitful because they would fuel further confusion rather than
providing clarity.
We think there are two major reasons for these problems.
First, each of the five new medicine paradigms has been
proposed before big genomic, clinical and electronic health
data have become widely available in an affordable manner.
For this reason it was not feasible to base a discussion on
a long lasting and practical hands-on experience. Even now
we haven’t fully reached this stage yet, but at least to some
extend, several such data sets of such sort are available, most
notably publicly provided by The Cancer Genome Atlas (TCGA)
(The Cancer Genome Atlas Research Network, 2008). This
deficiency of data, and the accompanying analysis expertise,
introduced inevitably some uncertainty in the formulation of
the proposed modern medicine programs and these gaps are
becoming presently more and more obvious and severe the
more data are actually becoming tangible. One expression of
this confusion could be observed during the 11th Annual
Personalized Medicine Conference 2015 held at the Harvard
Medical School in Boston, a prime conference in personalized
medicine, where the speakers could not present a coherent view,
e.g., in comparison with non-personalized medicine approaches.
Second, classically, medicine is the domain of practicing medical
doctors and clinicians, but there are well-known documented
problems in the understanding of statistical methodology by
these professions, even for comparably simple statistical analysis
tasks (Casscells et al., 1978; Manrai et al., 2014). Relating back
to large-scale Omics data, the required proficiency level for such
data is certainly manyfold higher and for this reason we think
it is fair to assume that an assigned committee should involve
experts from all relevant fields, including computational biology
and biostatistics, for the formulation of a modern medicine
program. In this context we would like to note that this was,
e.g., not the case for the Committee on a Framework for
Development a New Taxonomy of Disease, National Research
Council (2011).
We believe that modern medicine, in contrast to the
classical fields of medicine, should be a truely interdisciplinary
field and for this reason requires expertise from areas other
than medicine in a significant and profound manner. The
expertise that comes from the outside of medicine, needs
to be broadly centered around skill sets of the experimental
design of all types of relevant big data, including genomic,
clinical and health record data, as covered for instance by
computational biology, biostatistics and medical informatics.
This implies that every attempt for proposing a new paradigm
should be best based on a consortium of experts covering
all relevant fields, including the above mentioned quantitative
subjects. Furthermore, it seems impossible at the current
time to be able to achieve a final formulation in a one-
step process. For this reason a stepwise procedural approach
should be taken allowing the adjustment of such a formulation
over time by taking new developments into account. In
this way, the formulation of modern medicine could evolve
naturally.
The current state of this problem brings back when biology
transformed into a data-driven science at the beginning of the
millennium. Since then, computational biology and related fields
are providing an integral part by forming an inseparable unit with
biology, not only for providing services, but for leading the field.
We think that a similar transformation is needed for medicine
establishing computational medicine as an integral part of it
(Shah and Tenenbaum, 2012). Only in this way the experimental
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design needs of modern medicine are given full quantitative
considerations to make an efficient and integrative use of all
newly available biotechnologies producing data for providing the
best services for the patients.
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